Trends in Pharmaceutical Sciences and Technologies

Trends in Pharmaceutical Sciences and Technologies

Cytotoxicity of some 1-(2,4-dihydroxyphenyl)-3-(4-phenylpiperidin-1-yl) prop-2-en-1-one derivatives using MTT assay

Document Type : Research(Original) Article

Authors
Farzaneh Fesahat
Mehdi Khoshneviszadeh
Alireza Foroumadi
Alireza Vahidi
Maryam Fereidounpour
Amirhossein Sakhteman
Abstract
Some N-substituted piperidine structures were synthesized and evaluated for cytotoxic activity against four different cell lines using the standard MTT assay method and Doxorubicin was used as the reference drug. The result of cytotoxic activity as a measurement of IC50 values revealed that three of the synthesized compounds were active against breast cancer cell line. Compound 6a bearing hydroxyl at para position of piperidine ring was the most active compound within this series. The N-subtituted piperidine with propene substructure could be considered as a lead structure for further studies of structure activity relationship to develop more potent compounds in future.
  1. Ignatov T, Modl S, Thulig M, Weißenborn C, Treeck O, Ortmann O, et al. GPER-1 acts as a tumor suppressor in ovarian cancer. J Ovarian Res. 2013;6:51-61. doi: 10.1186/1757-2215-6-51
  2. Huang Y, Hu J, Zheng J, Li J, Wei T, Zheng Z, Chen Y. Down-regulation of the PI3K/Akt signaling pathway and induction of apoptosis in CA46 Burkitt lymphoma cells by baicalin. J Exp Clin. 2012;31:48 doi: 10.1186/1756-9966-31-48.
  3. Jemal A, Bray F, Center MM, et al, Global cancer statistics. CA Cancer J Clin. 2011;61:69-90. doi: 10.3322/caac.20107
  4. Speth PA, van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin. Clinical pharmacokinetics. 1988;15(1):15-31.
  5. La-Beck NM, Zamboni BA, Gabizon A, Schmeeda H, Amantea M, Gehrig PA, et al. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer chemotherapy and pharmacology. 2012;69(1):43-50 .doi: 10.1007/s00280-011-1664-2.
  6. Aghaee F, Islamian JP, Baradaran B, Mesbahi A, Mohammadzadeh M, Jafarabadi MA. Enhancing the Effects of Low Dose Doxorubicin Treatment by the Radiation in T47D and SKBR3 Breast Cancer Cells. Journal of breast cancer. 2013;16(2):164-70.
  7. Hofmann J, Ueberall F, Egle A, Grunicke H. B-859-35, a new drug with anti-tumor activity reverses multi-drug resistance. International journal of cancer Journal international du cancer. 1991;47(6):870-4.
  8. Poon GK, McCague R, Griggs LJ, Jarman M, Lewis IA. Characterisation of metabolites of 3-ethyl-3-(4-pyridyl)-piperidine-2,6-dione, a potential breast cancer drug. Journal of chromatography. 1991;572(1-2):143-57.
  9. Kankala S, Kankala RK, Balaboina R, Thirukovela NS, Vadde R, Vasam CS. Pd-N-heterocyclic carbene catalyzed synthesis of piperidine alkene-alkaloids and their anti-cancer evaluation. Bioorganic & medicinal chemistry letters. 2014;24(4):1180-3.
  10. Salome C, Narbonne V, Ribeiro N, Thuad F, Serova M, et al. Benzofuran derivatives as a novel class of inhibitors of mTOR signaling. Eur J Med Chem. 2014; 74(3);41-49.
  11. Sarzaeem A, Zare Mirakabadi A, Moradhaseli S, Morovvati H, Lotfi M. Cytotoxic effect of ICD-85 (venom-derived peptides) on HeLa cancer cell line and normal LK cells using MTT Assay. Archives of Iranian medicine. 2012;15(11):696-701.
  12. Sakhteman A, Foroumadi A, Sharifzadeh M, Amanlou M, Rayatnia F, Shafiee A. Synthesis and dopaminergic activity of some E-3-(piperidin-1-yl)-1-(4-substituted phenyl)prop-2-en-1-one derivatives. Bioorganic & medicinal chemistry. 2009;17(19):6908-13.
  13. Ulukaya E, Colakogullari M, Wood EJ. Interference by anti-cancer chemotherapeutic agents in the MTT-tumor chemosensitivity assay. Chemotherapy. 2004;50(1):43-50.
  14. Schuurs AH, Duivenvoorden HJ, van 't Hof MA. [Statistics for dentists (VIII). Student t-test]. Nederlands tijdschrift voor tandheelkunde. 1993;100(11):495-8.